# Safety and Immunogenicity of BBV121

> **NCT04478656** · PHASE1 · COMPLETED · sponsor: **Bharat Biotech International Limited** · enrollment: 48 (actual)

## Conditions studied

- Zika Virus Infection

## Interventions

- **BIOLOGICAL:** BBV121

## Key facts

- **NCT ID:** NCT04478656
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-03
- **Primary completion:** 2017-11-15
- **Final completion:** 2018-11-15
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478656, "Safety and Immunogenicity of BBV121". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04478656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*